Biomedical Engineering Reference
In-Depth Information
[112] Egholm M, Buchardt O, Christensen L, Behrens C, Freier SM, Driver DA, et al. PNA
hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-
bonding rules. Nature 1993;365:566-8.
[113] Jensen KK, Orum H, Nielsen PE, Norden B. Kinetics for hybridization of peptide nucleic
acids (PNA) with DNA and RNA studied with the BIAcore technique. Biochemistry
1997;36:5072-7.
[114] Vickers TA, Griffith MC, Ramasamy K, Risen LM, Freier SM. Inhibition of NF-kappa B
specific transcriptional activation by PNA strand invasion. Nucleic Acids Res 1995;23:
3003-8.
[115] Mologni L, Marchesi E, Nielsen PE, Gambacorti-Passerini C. Inhibition of promyelo-
cytic leukemia (PML)/retinoic acid receptor- and PML expression in acute promyelo-
cytic leukemia cells by anti-PML peptide nucleic acid. Cancer Res 2001;61:5468-73.
[116] Summerton J, Weller D. Morpholino antisense oligomers: design, preparation, and
properties. Antisense Nucleic Acid Drug Dev 1997;7:187-95.
[117] Hudziak RM, Barofsky E, Barofsky DF, Weller DL, Huang SB, Weller DD. Resistance
of morpholino phosphorodiamidate oligomers to enzymatic degradation. Antisense
Nucleic Acid Drug Dev 1996;6:267-72.
[118] Rayburn ER, Zhang R. Antisense, RNAi, and gene silencing strategies for therapy: mis-
sion possible or impossible? Drug Discov Today 2008;13:513-21.
[119] Hicke BJ, Stephens AW. Escort aptamers: a delivery service for diagnosis and therapy.
J Clin Invest 2000;106:923-8.
[120] Chu TC, Twu KY, Ellington AD, Levy M. Aptamer mediated siRNA delivery. Nucleic
Acids Res 2006;34:e73.
[121] Aouadi M, Tesz GJ, Nicoloro SM, Wang M, Chouinard M, Soto E, et al. Orally delivered
siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature 2009;
458:1180-4.
[122] Okumura A, Pitha PM, Harty RN. ISG15 inhibits Ebola VP40 VLP budding in an
L-domain-dependent manner by blocking Nedd4 ligase activity. Proc Natl Acad Sci
USA 2008;105:3974-9.
[123] Lv W, Zhang C, Hao J. RNAi technology: a revolutionary tool for the colorectal cancer
therapeutics. World J Gastroenterol 2006;12:4636-9.
[124] Kim SH, Jeong JH, Lee SH, Kim SW, Park TG. Local and systemic delivery of VEGF
siRNA using polyelectrolyte complex micelles for effective treatment of cancer.
J Control Release 2008;129:107-16.
[125] Lomas-Neira JL, Chung CS, Wesche DE, Perl M, Ayala A. In vivo gene silencing (with
siRNA) of pulmonary expression of MIP-2 versus KC results in divergent effects on
hemorrhage-induced, neutrophilmediated septic acute lung injury. J Leukoc Biol 2005;
77:846-53.
[126] Woodrow KA, Cu Y, Booth CJ, Saucier-Sawyer JK, Wood MJ, Saltzman WM.
Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded
with small-interfering RNA. Nat Mater 2009;8:526-33.
[127] Peer D, Park EJ, Morishita Y, Carman CV, Shimaoka M. Systemic leukocyte-
directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science
2008;319:627-30.
[128] Großhans H, Filipowicz W. The expanding world of small RNAs. Nature 2008;451:
414-16.
[129] Lim LP, Lau NC, Weinstein EG, Abdelhakim A, Yekta S, Rhoades MW, et al. The
microRNAs of Caenorhabditis elegans . Genes Dev 2003;17:991-1008.
Search WWH ::




Custom Search